Literature DB >> 22099873

Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD).

Yuan Qiu1, Gui-Lin Peng, Qi-Cai Liu, Fu-Li Li, Xu-Sen Zou, Jian-Xing He.   

Abstract

The application of gene therapy in cancer treatment is limited by non-specific targeting. In the present study, we constructed a recombinant plasmid, containing a carcinoembryonic antigen (CEA) promoter and double suicide genes thymidine kinase (TK) and cytosine deaminase (CD), henceforth referred to as pCEA-TK/CD. Our results showed that the CEA promoter can specifically drive target gene expression in CEA-positive lung cancer cells. In the presence of prodrugs 5-flucytosine and ganciclovir, pCEA-TK/CD transfection decreased inhibitory concentration 50 and increased apoptosis and cyclomorphosis. Our result suggests that gene therapy using pCEA-TK/CD may be a promising new approach for treating lung cancer. Crown
Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099873     DOI: 10.1016/j.canlet.2011.10.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Proliferation inhibition and apoptosis enhancement of human cervical cancer cells by ultrasound-targeted microbubble destruction delivered double suicide genes.

Authors:  Yi Hao; Li Guo; Abulizi Abudula; Wuliyati Saidoula; Xia Guo
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Authors:  Chris G Twitty; Oscar R Diago; Daniel J Hogan; Cindy Burrascano; Carlos E Ibanez; Douglas J Jolly; Derek Ostertag
Journal:  Hum Gene Ther Methods       Date:  2015-12-01       Impact factor: 2.396

3.  Cytotoxic effect of co-expression of human hepatitis A virus 3C protease and bifunctional suicide protein FCU1 genes in a bicistronic vector.

Authors:  Alexey Komissarov; Ilya Demidyuk; Dina Safina; Marina Roschina; Andrey Shubin; Nataliya Lunina; Maria Karaseva; Sergey Kostrov
Journal:  Mol Biol Rep       Date:  2017-07-26       Impact factor: 2.316

4.  A Brief Introduction to Current Cancer Gene Therapy.

Authors:  Dennis Kobelt; Jessica Pahle; Wolfgang Walther
Journal:  Methods Mol Biol       Date:  2022

5.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

6.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

7.  A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.

Authors:  Kai Wu; Liucheng Yang; Zonghai Huang; Haijun Zhao; Jianjun Wang; Shuai Xu
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

8.  Lentivirus-mediated RASSF1A expression suppresses aggressive phenotypes of gastric cancer cells in vitro and in vivo.

Authors:  P-H Zhou; J-B Zheng; G-B Wei; X-L Wang; W Wang; N-Z Chen; J-H Yu; J-F Yao; H Wang; S-Y Lu; X-J Sun
Journal:  Gene Ther       Date:  2015-05-25       Impact factor: 5.250

9.  Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.

Authors:  Ana Rosa Rama Ballesteros; Rosa Hernández; Gloria Perazzoli; Laura Cabeza; Consolación Melguizo; Celia Vélez; Jose Prados
Journal:  Cancer Gene Ther       Date:  2019-09-24       Impact factor: 5.987

10.  A triple suicide gene strategy that improves therapeutic effects and incorporates multimodality molecular imaging for monitoring gene functions.

Authors:  L Xing; X Sun; X Deng; K Kotedia; P B Zanzonico; E Ackerstaff; J A Koutcher; C C Ling; G C Li
Journal:  Cancer Gene Ther       Date:  2013-05-31       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.